OTLK - Outlook gets EU approval for Lytenava for wet AMD
2024-05-28 11:50:44 ET
More on Outlook Therapeutics
- Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
- Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval
- Outlook Therapeutics shares rise after 'buy' rating from BTIG
- Outlook Therapeutics stock jumps as EU backs new wet AMD treatment
- Seeking Alpha’s Quant Rating on Outlook Therapeutics